Is Individualized Medicine More Cost-Effective? A Systematic Review
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is Individualized Medicine More Cost-Effective? A Systematic Review
Authors
Keywords
Human Epidermal Growth Factor Receptor, Idiopathic Pulmonary Fibrosis, Lynch Syndrome, MeSH, National Comprehensive Cancer Network
Journal
PHARMACOECONOMICS
Volume 32, Issue 5, Pages 443-455
Publisher
Springer Nature
Online
2014-02-26
DOI
10.1007/s40273-014-0143-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
- (2013) Mark H. Eckman ANNALS OF INTERNAL MEDICINE
- Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer
- (2013) Uri Ladabaum et al. ANNALS OF INTERNAL MEDICINE
- Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia
- (2013) Michael J. Sorich et al. PHARMACOECONOMICS
- Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
- (2012) Masahide Kondo et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
- (2012) Nathan W. D. Lamond et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
- (2012) Calogero Cammà et al. HEPATOLOGY
- Endogenous cost-effectiveness analysis and health care technology adoption
- (2012) Anupam B. Jena et al. JOURNAL OF HEALTH ECONOMICS
- Personalized oncology: Recent advances and future challenges
- (2012) Madhu Kalia METABOLISM-CLINICAL AND EXPERIMENTAL
- Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
- (2012) Eric Faulkner et al. VALUE IN HEALTH
- Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance
- (2011) Valesca P. Retèl et al. BREAST CANCER RESEARCH AND TREATMENT
- KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
- (2011) P. R. Blank et al. CLINICAL CANCER RESEARCH
- A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy
- (2011) Jodie Ingles et al. HEART
- Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses
- (2011) John P. A. Ioannidis JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Testing Women With Endometrial Cancer to Detect Lynch Syndrome
- (2011) Janice S. Kwon et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer
- (2011) Peter S. Hall et al. JNCI-Journal of the National Cancer Institute
- Economic Opportunities and Challenges for Pharmacogenomics
- (2010) Patricia A. Deverka et al. Annual Review of Pharmacology and Toxicology
- Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population
- (2010) T. A. Dinh et al. Cancer Prevention Research
- Cost-Effectiveness of Genetic Testing in Family Members of Patients With Long-QT Syndrome
- (2010) Marco V. Perez et al.
- Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
- (2010) Valesca P. Retèl et al. EUROPEAN JOURNAL OF CANCER
- The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer
- (2010) Mercy Mvundura et al. GENETICS IN MEDICINE
- Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis
- (2010) Jared T. Hagaman et al. LUNG
- Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities
- (2010) Rena Conti et al. MEDICAL DECISION MAKING
- Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
- (2010) D. T. Tsoi et al. ONCOLOGIST
- Cost Effectiveness of Pharmacogenomics
- (2010) William B. Wong et al. PHARMACOECONOMICS
- Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
- (2010) Shmuel H. Klang et al. VALUE IN HEALTH
- Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy
- (2009) J H S You et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study
- (2009) Roy H Perlis et al. NEUROPSYCHOPHARMACOLOGY
- Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes
- (2009) Stefan Vegter et al. PHARMACOECONOMICS
- 30 Years of Pharmaceutical Cost-Utility Analyses
- (2009) Peter J. Neumann et al. PHARMACOECONOMICS
- A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
- (2009) Lisa M. Meckley et al. PHARMACOECONOMICS
- Pharmacogenomics and Public Health
- (2009) D. Veenstra et al. Public Health Genomics
- Pharmacogenomics, Evidence, and the Role of Payers
- (2009) P.A. Deverka Public Health Genomics
- Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa
- (2008) Arthi Vijayaraghavan et al. GYNECOLOGIC ONCOLOGY
- Payer perspectives on pharmacogenomics testing and drug development
- (2008) Robert S Epstein et al. PHARMACOGENOMICS
- Cost-Effectiveness of Testing for Breast Cancer Susceptibility Genes
- (2008) Margaret L. Holland et al. VALUE IN HEALTH
- The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer
- (2008) Josh J. Carlson et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More